Artificial intelligence to improve drug combination design and personalized medicine

Artificial intelligence to improve drug combination design & personalized medicine
Harnessing Artificial Intelligence toImprove Drug Combination Design and Personalized Medicine. Credit: Zac Goh

A new auto-commentary published in SLAS Technology looks at how an emerging area of artificial intelligence, specifically the analysis of small systems-of-interest specific datasets, can be used to improve drug development and personalized medicine. The auto-commentary builds on a study recently published by the authors in Science Translational Medicine about an artificial intelligence (AI) platform, Quadratic Phenotypic Optimization Platform (QPOP), that substantially improves combination therapy in bortezomib-resistant multiple myeloma to identify the best drug combinations for individual multiple myeloma patients.

It is now evident that complex diseases, such as cancer, often require effective combinations to make any significant therapeutic impact. As the drugs in these combination therapies become increasingly specific to molecular targets, designing effective drug combinations as well as choosing the right drug combination for the right patient becomes more difficult.

Artificial intelligence is having a positive impact on and personalized medicine. With the ability to efficiently analyze small datasets that focus on the specific disease of interest, QPOP and other small dataset-based AI platforms can rationally design optimal drug combinations that are effective and based on real experimental data and not mechanistic assumptions or predictive modeling. Furthermore, because of the efficiency of the platform, QPOP can also be applied towards precious patient samples to help optimize and personalize combination therapy.


Explore further

Researchers develop AI platform to rapidly identify optimal personalised drug combinations for myeloma patients

More information: Masturah Bte Mohd Abdul Rashid et al, Artificial Intelligence-Driven Designer Drug Combinations: From Drug Development to Personalized Medicine, SLAS TECHNOLOGY: Translating Life Sciences Innovation (2018). DOI: 10.1177/2472630318800774

Masturah Bte Mohd Abdul Rashid et al. Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP), Science Translational Medicine (2018). DOI: 10.1126/scitranslmed.aan0941

Journal information: Science Translational Medicine

Provided by SLAS (Society for Laboratory Automation and Screening)
Citation: Artificial intelligence to improve drug combination design and personalized medicine (2018, September 25) retrieved 18 June 2019 from https://phys.org/news/2018-09-artificial-intelligence-drug-combination-personalized.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
108 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more